Sanofi
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!About SNY
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.
CEOPaul Hudson
CEOPaul Hudson
Employees84,587
Employees84,587
HeadquartersParis, Ile-de-France
HeadquartersParis, Ile-de-France
Founded1994
Founded1994
Employees84,587
Employees84,587
SNY Key Statistics
Market cap132.16B
Market cap132.16B
Price-Earnings ratio22.06
Price-Earnings ratio22.06
Dividend yield2.79%
Dividend yield2.79%
Average volume4.02M
Average volume4.02M
High today$53.09
High today$53.09
Low today$52.30
Low today$52.30
Open price$52.46
Open price$52.46
Volume3.05M
Volume3.05M
52 Week high$60.12
52 Week high$60.12
52 Week low$45.80
52 Week low$45.80
SNY News
TipRanks 2h
Innate Pharma announces EUR 15M capital increase from SanofiInnate Pharma (IPHA) announced a EUR 15M capital increase subscribed by Sanofi (SNY). As announced on April 23 and given the satisfactory market conditions, San...
TipRanks 22h
Innate Pharma Regains Rights on CD123 ANKET® and Announces Sanofi’s Strategic InvestmentInnate Pharma SA ( (FR:IPH) ) just unveiled an announcement. Innate Pharma announced on April 23, 2025, that it will regain its rights to the CD123 targeting A...
TipRanks 2d
Sanofi’s Dupixent Gains FDA Approval for Chronic Spontaneous UrticariaSanofi ( (SNY) ) has issued an update. On April 18, 2025, Sanofi announced that the US FDA approved Dupixent as the first new targeted therapy in over a decade...
Analyst ratings
80%
of 25 ratingsBuy
80%
Hold
16%
Sell
4%
More SNY News
TipRanks 6d
Regeneron, Sanofi announce FDA approval of Dupixent for CSURegeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and ado...